Increased Level of Fibroblast Growth Factor 19 in Patients with Ulcerative Colitis in Remission

Panek-Jeziorna, Magdalena; Jasińska, Maria; Marczak-Karpina, Beata; Mulak, Agata

doi:10.1016/s0016-5085(17)33290-0

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Based on the available literature data, it has been estimated that BA malabsorption is present in about 1% of UC patients [17]. In two recent studies, it has been shown that the FGF19 level was normal [17] or slightly elevated [18] compared to the controls which is consistent with our own preliminary results [19]. In the current study, primary sclerosing cholangitis was an exclusion criterion and in none of the patients with nonactive UC, any signs of cholestasis were detected.…”

Section: Discussionsupporting

confidence: 91%

An Inverse Correlation of Serum Fibroblast Growth Factor 19 with Abdominal Pain and Inflammatory Markers in Patients with Ulcerative Colitis

Panek-Jeziorna

Mulak

2020

Gastroenterology Research and Practice

Self Cite

View full text Add to dashboard Cite

Background and Aims. Bile acids (BA) play an important role in the modulation of numerous gut functions. Fibroblast growth factor 19 (FGF19) is the ileal hormone regulating BA homeostasis. The aim of the study was to evaluate serum FGF19 level and its correlation with clinical and endoscopic disease activity indices along with inflammatory biomarkers including serum CRP and fecal calprotectin levels in patients with ulcerative colitis (UC). Methods. Fasting serum FGF19 level was measured using ELISA test in 16 patients with active UC (7 F, 9 M), 15 patients with nonactive UC (8 F, 7 M), and 19 healthy controls (11 F, 8 M). The disease activity was assessed based on the clinical and endoscopic evaluations as well as serum CRP and fecal calprotectin level measurement. Results. The median serum FGF19 level was higher in patients with nonactive UC (175.3 pg/ml (108.7-342.3)) than in patients with active UC (114.3 pg/ml (68.9-155.3), p=0.093). The median FGF19 level in healthy controls amounted to 151.6 pg/ml (90.6-224.2), and there were no statistically significant differences between the patients with active and nonactive UC compared to the healthy controls. An inverse correlation was observed between FGF19 level and abdominal pain intensity (R=–0.48, p=0.007) as well as fecal calprotectin (R=–0.38, p=0.036) and CRP levels (R=–0.36, p=0.045). The serum FGF19 level was not correlated neither with clinical nor endoscopic disease activity indices. Conclusions. The inverse correlations between FGF19 level and abdominal pain as well as inflammatory markers in UC may imply its potential analgesic and anti-inflammatory effects.

show abstract